Perspectives

David Lassen Shares Insights on Prime/MRx Analysis on GLP-1 for Weight Loss in New Video

October 31, 2023

Earlier this year, Prime Therapeutics/Magellan Rx (Prime/MRx) announced a real-world analysis of glucagon-like peptide-1 agonist (GLP-1a) drugs for weight loss, which found low adherence and increased cost among individuals taking the drug after one year.

WATCH: David Lassen, Chief Clinical Officer at Prime/MRx, shares additional insights on this study

As GLP-1a drugs continue to alter the health care landscape, Prime/MRx subject matter experts will continue keep the pulse on this dynamic trend with trusted data and insights. Check our news page for regular updates.

VISIT OUR GLP-1 LANDING PAGE

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

May 1, 2024

Prime Therapeutics releases new clinical insights report, “Weight management: A holistic journey”

Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss

Read More

Perspectives

April 30, 2024

AMCP 2024: Behind the GLP-1 Spotlight Session with Ben Urick

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Read More

Perspectives

April 30, 2024

Quarterly Drug Pipeline

Clinical insights and competitive intelligence on anticipated drugs in development

Read More
View all news